questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Enzymes activatrices du complément
Complement C3-C5 Convertases
Complement C3-C5 Convertases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience du complément
Tests de laboratoire
Tests de complément
Hémolyse
Infections
Maladies auto-immunes
Sérum
Activité enzymatique
Symptômes
5
Éruptions cutanées
Douleurs articulaires
Troubles neurologiques
Inflammation cérébrale
Infections bactériennes
Maladies auto-immunes
Déficience du complément
Symptômes cliniques
Prévention
5
Prévention
Diagnostic précoce
Alimentation équilibrée
Nutrition
Suivi médical
Complications
Conseils génétiques
Transmission héréditaire
Traitements
5
Immunoglobulines
Antibiotiques
Médicaments anti-inflammatoires
Inhibiteurs du complément
Transfusions sanguines
Protéines du complément
Thérapie génique
Déficiences génétiques
Médecine personnalisée
Soins individualisés
Complications
5
Infections graves
Maladies auto-immunes
Complications réversibles
Gestion des complications
Qualité de vie
Douleurs chroniques
Complications neurologiques
Troubles cognitifs
Lésions tissulaires
Réactions inflammatoires
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections fréquentes
Déficience du complément
Maladies génétiques
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes",
"headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-14",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes activatrices du complément",
"url": "https://questionsmedicales.fr/mesh/D003166",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes activatrices du complément",
"code": {
"@type": "MedicalCode",
"code": "D003166",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D050578",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051561",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051566",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051566",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D050579",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Classical pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051574",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051577",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"alternateName": "Mannose-Binding Protein-Associated Serine Proteases",
"url": "https://questionsmedicales.fr/mesh/D050606",
"about": {
"@type": "MedicalCondition",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"code": {
"@type": "MedicalCode",
"code": "D050606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050577",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John D Lambris",
"url": "https://questionsmedicales.fr/author/John%20D%20Lambris",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Tom Eirik Mollnes",
"url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes",
"affiliation": {
"@type": "Organization",
"name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway."
}
},
{
"@type": "Person",
"name": "Dimitrios C Mastellos",
"url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos",
"affiliation": {
"@type": "Organization",
"name": "National Center for Scientific Research 'Demokritos', Athens, Greece."
}
},
{
"@type": "Person",
"name": "Giuseppe Remuzzi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy."
}
},
{
"@type": "Person",
"name": "Markus Huber-Lang",
"url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluation of bone mineral density and bone turnover in children on anticoagulation.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37600706",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1192670"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraoperative physician assessment of bone: correlation to bone mineral density.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/37000208",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00198-023-06729-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Influence of bone density on stability in TBW.",
"datePublished": "2023-11-15",
"url": "https://questionsmedicales.fr/article/37968632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12891-023-07007-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Bone mineral density in vegetarians and vegans].",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37432709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33029/0042-8833-2023-92-3-69-78"
}
},
{
"@type": "ScholarlyArticle",
"name": "Phthalates and bone mineral density: a systematic review.",
"datePublished": "2022-11-12",
"url": "https://questionsmedicales.fr/article/36369032",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12940-022-00920-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Enzymes activatrices du complément",
"item": "https://questionsmedicales.fr/mesh/D003166"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complement C3-C5 Convertases",
"item": "https://questionsmedicales.fr/mesh/D050577"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complement C3-C5 Convertases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complement C3-C5 Convertases",
"description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complement C3-C5 Convertases",
"description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complement C3-C5 Convertases",
"description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complement C3-C5 Convertases",
"description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complement C3-C5 Convertases",
"description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complement C3-C5 Convertases",
"description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Bone+Density#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en convertases C3-C5 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du complément ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques suggèrent une activation du complément ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des convertases dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux convertases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation excessive du complément ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles liés aux convertases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "Les troubles du complément causent-ils des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déficience en C3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de déficience ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en complément ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à prévenir les complications ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en complément ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques."
}
},
{
"@type": "Question",
"name": "Comment traiter une activation excessive du complément ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines aident-elles en cas de déficience ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en C3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées à l'activation excessive du complément ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déficience en complément ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles du complément ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les troubles du complément ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
7 publications dans cette catégorie
Affiliations :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Complement C3-C5 Convertases" :
Childhood and adolescence are critical periods of bone mineral acquisition. Children on anticoagulation (AC) might have an increased risk for reduced bone mineral density (BMD). Risk factors for impai...
To evaluate BMD in children on AC and characterize the risk factors of low BMD, including VK and Vitamin D (VD) status....
Single-center cross-sectional study of clinical, biochemical, and densitometric parameters. Assessment of VK surrogate parameters included ucOC and matrix gla protein (MGP)....
A total of 39 children (4-18 years; 12 females) receiving AC were included, 31 (79%) on VK antagonists and 8 (21%) on direct oral anticoagulants. Overall, BMD was decreased for both the lumbar spine (...
Our data indicate BMD reduction in pediatric patients on AC. Although AC-related factors did not predict reduced BMD, low BMI and pubertal stages represented important risk factors. Awareness of risk ...
This study evaluated the intraoperative physician assessment (IPA) of bone status at time of total knee arthroplasty. IPA was highly correlated with distal femur and overall bone mineral density. When...
Intuitively, intraoperative physician assessment (IPA) would be an excellent measure of bone status gained through haptic feedback during bone preparation. However, no studies have evaluated the ortho...
Seventy patients undergoing TKA by 3 surgeons received pre-operative DXA. Intraoperatively, bone quality was assessed on a 5-point scale (1 excellent to 5 poor) based on tactile feedback to preparatio...
The mean (SD) age and BMI were 65.8 (7.6) years and 31.4 (5.1) kg/m...
IPA is highly correlated with local (distal femur) and overall BMD. This study supports the International Society for Clinical Densitometry position that surgeon concern regarding bone quality should ...
Osteoporosis is a common disease that leads to a reduction in bone density and increases the risk of fractures. Stable surgical treatment is particularly important for these fractures. The aim of this...
The number of vegetarians and vegans is increasing each year. In this regard, studies of the quality of diets that exclude slaughter foods, as well as their impact on human health, are becoming more a...
Exposure to endocrine disruptors, such as phthalates, may impact bone mineral density (BMD) through a variety of mechanisms. Studies of phthalate exposure and BMD in humans are scarce....
To synthesize published data on the association between phthalate metabolites and BMD in humans and to provide methodological suggestions for future research....
A single investigator searched PubMed for relevant studies, including observational studies of phthalate exposure and BMD in children and postmenopausal women. Twelve studies were screened with 5 meet...
In one prospective study among postmenopausal women, higher levels of monocarboxyoctyl phthalate (MCOP) and monocarboxynonyl phthalate (MCNP) were significantly associated with lower BMD among nonuser...
Studies among postmenopausal women provide suggestive evidence of an association between urinary phthalate metabolite concentration and decreased BMD. Results from studies of childhood BMD are inconcl...
Sagittal spinal malalignment often leads to surgical realignment, which is associated with major complications. Low bone mineral density (BMD) and impaired bone microstructure are risk factors for ins...
A retrospective, cross-sectional study of patients who underwent lumbar fusion for degeneration was conducted. The vBMD of the lumbar spine was assessed by quantitative computed tomography. Bone biops...
A total of 172 patients (55.8% female, 63.3 years, BMI 29.7 kg/m...
Sagittal malalignment is associated with lower lumbar vBMD and trabecular microstructure. Lumbar vBMD was significantly lower in patients with malalignment. These findings warrant attention, as malali...
The aims of the study were to determine the mean trabecular bone score (TBS) of postmenopausal Taiwanese women and to analyze the value of TBS in predicting osteoporosis....
A total of 1,915 postmenopausal women with lumbar spine and hip bone mineral density (BMD) and spine TBS were enrolled from a single medical center into this study. The women's BMD and TBS were measur...
The average age of the women was 62.5 ± 9.1 years (range, 25.7-93.7 years). The mean TBS was 1.300 ± 0.086 (range, 1.015-1.596). The TBS was weakly and negatively correlated with body mass index ( r =...
Bone mineral density and TBS can be used in combination to predict osteoporosis in a greater number of postmenopausal Taiwanese women. Because the incidence of osteoporosis is the highest among older ...
Children with haemophilia (CwH) have lower bone mineral density in the spine (trabecular bone) than healthy children. There are few studies focusing on bone mineral density in long bones (cortical bon...
To evaluate bi-laterally the distal third of radius and midshaft tibias using quantitative ultrasound (QUS) and assess the speed of sound (SoS)....
A cross-sectional study where 91 CwH and 91 age-matched healthy boys were included. Joint evaluation was determined with the Haemophilia Joint Health Score 2.1 and SoS values. The Z scores were measur...
Ninety-one CwH (haemophilia A) were evaluated (26 mild form, 26 moderate, and 39 severe). Most patients were treated with on-demand factor replacement and had higher total HJHS scores according to sev...
There was diminished cortical bone density in radius and tibias of CwH compared to healthy controls. Changes predominated in tibias, more frequently affected according to the severity of haemophilia. ...
Low bone mineral density (BMD) and dementia commonly co-occur in older individuals, with bone loss accelerating in patients with dementia due to physical inactivity and poor nutrition. However, uncert...
In a prospective population-based cohort study, BMD at the femoral neck, lumbar spine, and total body and the trabecular bone score (TBS) were obtained using dual-energy X-ray absorptiometry in 3,651 ...
Among the 3,651 participants (median age 72.3 ± 10.0 years, 57.9% women), 688 (18.8%) developed incident dementia during a median of 11.1 years, of whom 528 (76.7%) developed Alzheimer disease (AD). D...
In conclusion, participants with low femoral neck and total body BMD and low TBS were more likely to develop dementia. Further studies should focus on the predictive ability of BMD for dementia....
Bone health in primary ovarian insufficiency (POI) is under-investigated. We assessed patients with spontaneous POI for vertebral fractures (VFs) and related parameters of bone health....
70 cases with spontaneous POI (age 32.5 ± 7.0 years) and an equal number of controls were assessed for BMD, TBS, and VFs. BMD at the lumbar-spine (L1-L4), left hip, non-dominant forearm, and TBS (iNsi...
BMD at the lumbar-spine, hip and forearm was reduced by 11.5%, 11.4% and 9.1% in POI as compared to controls (P < 0.001). Degraded or partially degraded microarchitecture on TBS was observed in 66.7% ...
Thus, lumbar-spine osteoporosis, impaired TBS and VFs were present in 35.7%, 66.7% and 15.7% of patients with spontaneous POI in their early third decade. This indicates need for rigorous investigatio...
